MarketPulse

eye drops

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Oculis Holding Ag

Oculis to Showcase Late-Stage Pipeline at ARVO 2026 Amid Key DME Trial Readout

Oculis will present its ophthalmology pipeline at ARVO 2026, with Phase 3 results for lead DME candidate OCS-01 expected in June.
OCSOCSAWclinical trialsdiabetic macular edema
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Oculis to Showcase Late-Stage Pipeline at ARVO 2026 as OCS-01 Phase 3 Data Nears

Oculis to present advancing ophthalmology pipeline at ARVO 2026, with Phase 3 OCS-01 DME results expected June 2026.
OCSOCSAWPhase 3 clinical trialdiabetic macular edema